Developing an inhaled biologic requires more than adapting a conventional formulation to a new route of administration. It begins with a detailed understanding of the molecule itself, including its three-dimensional structure, physicochemical properties, degradation pathways and response to the stresses associated with aerosolisation.
This webinar will explore how molecular characterisation, in silico modelling and predictive formulation science can help identify critical liabilities earlier, guide stabilisation strategies and inform the choice between liquid and dry-powder delivery.
Attendees will gain a practical, data-driven perspective on how to reduce reliance on empirical trial and error and build a stronger scientific foundation for inhaled biologic development.
Join us as we decode the complex scientific challenges that shape inhaled biologic development. From molecular structure and stability assessment to formulation strategy and delivery-pathway selection, discover a practical roadmap for turning promising biologic candidates into viable inhaled medicines. Register now to secure your spot.
Key Learning Objectives
- Gain a deeper understanding of how molecular structure influences biologic stability and inhalation performance.
- Discover how predictive science can inform formulation decisions and accelerate development timelines.
- Understand the key considerations involved in selecting the most appropriate inhalation delivery pathway for a biologic candidate.
